Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026. Three of them stand out for July: a beaten-down quick-service leader, a biopharma machine firing on all cylinders, and a home improvement giant priced for a housing recovery that hasn’t fully arrived. Each pick offers a verified payout, a forward-looking thesis, and a clear risk to weigh.
McDonald’s (NYSE: MCD)
McDonald’s (NYSE:MCD | MCD Price Prediction) is the classic “buy the weakness” setup right now. Shares traded around $275 on Monday, July 6, down more than 9% year to date and more than 6% over the past year. That underperformance has pushed the yield to 2.71% on an annualized payout of $7.26 per share.
The dividend record is the anchor. Alpha Vantage data confirms an unbroken quarterly dividend history from 1999 through 2026, with the most recent bump from $1.77 to $1.86 per share. McDonald’s has raised its payout for decades, comfortably clearing the Aristocrat bar.
Operationally, the business is working. Q1 2026 delivered EPS of $2.83 vs. $2.74 expected, revenue of $6.52 billion (up 9% YoY), and global comparable sales up 4%. CEO Chris Kempczinski said “McDonald’s delivered this quarter. Our 6% global Systemwide sales growth shows how we executed with discipline.” Food services spending in the broader economy supports the setup: PCE data shows food services climbing to $1,538.3 billion in May 2026, up steadily from January.
Risk: Margin pressure from inflationary cost pressures, tariffs, and intense QSR competition could cap upside. A forward P/E of 21 isn’t cheap if comp growth stalls.
AbbVie (NYSE: ABBV)
AbbVie (NYSE:ABBV) is the momentum name in this trio. The stock is up 14% over the past month, 11% year-to-date and 36% over the trailing year. The yield sits at 2.71% on an annualized payout of $6.74 per share.
A note on the Aristocrat label: AbbVie’s standalone dividend streak runs 12 consecutive years (2013 through 2026) since its spin-off from Abbott Laboratories on January 1, 2013. Counting the combined Abbott lineage gets you to the traditional 25-year threshold, but on a standalone basis, it’s a 12-year streak that has grown the quarterly payout from $0.40 to $1.73.
The growth engine has fully replaced Humira. Q1 2026 revenue hit $15 billion (up 12% YoY), with Skyrizi at $4.48 billion (+31%) and Rinvoq at $2.12 billion (+23%). Management raised 2026 adjusted EPS guidance to $14.08-$14.28. CEO Robert A. Michael said AbbVie is “off to an excellent start in 2026, with first-quarter results exceeding our expectations.”
Risk: Humira biosimilar erosion remains brutal, with the franchise down 50% in FY25, and the balance sheet carries negative shareholders’ equity. After the recent rally, valuation is stretched on a trailing basis.
Lowe’s (NYSE: LOW)
Lowe’s (NYSE:LOW) is the contrarian pick. Shares traded around $221.95 on Monday, July 6, down 10% year-to-date despite a nearly 7% bounce over the past month. The quarterly dividend just stepped up to $1.25, with the next ex-date July 22.
The streak is real Aristocrat material. Alpha Vantage data shows consistent year-over-year dividend increases from 1999 through 2026, with the Q2 payout climbing from 3 cents in 1999 to $1.20 in 2026.
The thesis hinges on the housing lock-in trade. Existing home sales sit at 4.17 million annualized in May 2026, still below the 4.5–5.5M healthy band. That keeps homeowners in place and pushes renovation spending. Furnishings PCE has accelerated to $531.6 billion in May 2026 from $516.7 billion in January. Q1 FY2027 results showed revenue up 10% YoY to $23.08 billion, the fourth consecutive quarter of positive comps, and online sales up 16%. CEO Marvin R. Ellison cited “strong spring execution and continued momentum in Pro, Appliances, Online, and Home Services.” FY2026 guidance calls for adjusted diluted EPS of $12.25–$12.75.
Risk: Housing starts dropped 15% month-over-month in May to 1.177 million units, a warning that new construction demand is slowing. Combined with margin compression from recent acquisitions and tariff exposure, the recovery could take longer than bulls expect.
Bottom Line
These three names cover different macro lanes: McDonald’s offers value and global QSR exposure at a discount, AbbVie delivers growth-driven income momentum, and Lowe’s lets investors lean into the home improvement cycle while collecting a rising payout. For income investors building a July watchlist, the combination of yield, growth, and verified dividend track records makes each worth a closer look.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks